May 21, 2018 08:15 AM EDT
Pharma

Long side­lined on man­u­fac­tur­ing penal­ties, As­traZeneca fi­nal­ly gets a green light for a po­ten­tial hy­per­kalemia block­buster

John Carroll

Editor & Founder

Af­ter be­ing forced to the side­lines as Vi­for cleaned up its prob­lems with its hy­per­kalemia drug Veltas­sa and bur­nished hopes for big sales, As­traZeneca is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times